FIGURE 5.

Effects of sequential treatment with (d‐Arg³⁵)‐sea lamprey (SL)‐PYY and liraglutide on pancreatic islet morphology in HFF‐STZ mice. Pancreatic (A) Islet‐, (B) Beta‐, (C) Alpha‐cell areas and (D) Percentage centrally glucagon positive staining cells were assessed after 28 days of twice‐daily (08:00 AM and 08:00 PM) treatment with liraglutide alone (0.25 nmol/kg bw) or SL‐PYY (75 nmol/kg bw) at 08:00 AM and liraglutide (0.25 nmol/kg bw) at 08:00 PM. (E) Representative islet images showing insulin (red), glucagon (green) and DAPI (blue) from each treatment group. Values are mean ± SEM for n = 8 mice. *P < .05 and ***P < .001 compared with saline‐treated HFF‐STZ control mice. ^ΔΔ P < .01 compared with twice‐daily liraglutide‐treated HFF‐STZ mice. DAPI, 4',6‐diamidino‐2‐phenylindole; HFF, high fat fed; PYY, peptide tyrosine; STZ, streptozotocin